T cell AIM2 Exacerbates Lung Inflammation in OVA-LPS and HDM-induced Asthma Models

Asthma is a complex airway inflammatory disease characterized by immune dysregulation, with diverse cellular contributors to inflammation that result in airway hyperresponsiveness (AHR) and excessive immune responses. The role of the inflammasome in asthma is conflicted. AIM2 is an innate immune receptor that activates the inflammasome through DNA binding. The clinical relevance of AIM2 in asthma is supported by analysis of blood or endobronchial biopsies from patients with severe asthma, showing increased AIM2 but not NLRP3 expression. We investigated the role of AIM2 in allergic asthma using ovalbumin (OVA)-LPS and house dust mite (HDM)- induced models. AIM2 expression was elevated in lung homogenates and bronchoalveolar lavage fluid (BALF) cells from allergen-induced groups compared to controls. In the OVA-LPS model, deletion of Aim2 led to reduced airway smooth muscle actin expression and DNA damage, contributing to decreased AHR and lung inflammation in whole body Aim2-/- mice. Surprisingly, cell-specific deletion in CD4+ T cells but not regulatory T cells or myeloid cells significantly affected AHR, indicating AIM2 in CD4+ T cells is a main driver of pathogenesis. Additionally, in HDM-induced asthma, Aim2-/- mice also exhibited reduced AHR. Cell-specific deletion reveals that AIM2 in CD4+ T cells promotes AHR and cytokine production, while AIM2 in myeloid cells modulates IgG1 levels and IL-13-producing CD4+ T cells, and the percentage of alveolar macrophages in BALF. These findings reveal that AIM2 differentially regulates HDM-induced allergic asthma through distinct exacerbating roles in T cells and myeloid cells, highlighting its potential as a therapeutic target. SignificanceAllergic asthma is a complex, heterogeneous disease characterized by airway inflammation and hyper-responsiveness. AIM2, an inflammasome activated by DNA, has emerged as a critical regulator of inflammatory diseases. In humans, AIM2 expression is elevated in severe asthma. In vivo studies highlight AIM2 as a key modulator of allergic asthma in both OVA-LPS and HDM- induced models. Surprisingly, its functional relevance in both models is mediated by its intrinsic role in T cells, while a modest role in myeloid cells is restricted to the HDM model. AIM2 promotes airway hyper-responsiveness and lung inflammation through enhancing type II cytokines, immune subpopulations and DNA damage response. These findings suggest AIM2 as a biomarker and therapeutic target for managing asthma, particularly in severe asthma subtypes.